Rivanol Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is the compendial active pharmaceutical ingredient ethacridine lactate monohydrate, 6,9-diamino-2-ethoxyacridine lactate monohydrate, CAS 6402-23-9, molecular formula C18H23N3O5 and relative molecular mass 361.39 g/mol. The material is released as a yellow crystalline powder with the acridine chromophore responsible for visible absorption in the 400–450 nm region. Unlike a finished antiseptic solution, the veterinary-grade API is supplied as a solid monohydrate for downstream formulation into the dosage forms named in the product description; the term “Solution” refers to the intended aqueous administration form and to the API’s primary use as a water-soluble active. Specification alignment with the Ph. Eur. monograph 1507 for ethacridine lactate monohydrate and current ICH Q7 good manufacturing practice are standard for bulk release.

Release testing includes assay by anhydrous titration with perchloric acid, with a typical acceptance range of 98.5–101.0% on the dried basis. Loss on drying is controlled within 4.0–5.5% to maintain the monohydrate crystal lattice; sulfated ash does not exceed 0.1% under Ph. Eur. 2.4.14, and related substances by liquid chromatography are limited to total impurities not more than 1.0%. Elemental impurities follow ICH Q3D with parenteral routes triggering lower permitted daily exposures for cadmium, lead and arsenic than oral or topical routes. Residual solvents, where ethanol may be present from recrystallisation, are controlled under ICH Q3C with ethanol as a Class 3 solvent at not more than 5000 ppm. The powder should be stored at 15–25°C in tight, light-resistant containers; the monohydrate is stable for 24 months when protected from moisture excursions above 60% RH.

Because the product is an active pharmaceutical ingredient rather than a finished veterinary medicinal product, no single model number appears in pharmacopoeial monographs. Batch release is identified by the manufacturer’s lot number, the compendial designation and the country-specific veterinary drug approval file. Buyers should request a certificate of analysis and material safety data sheet before use.

What Are the Compounding Boundaries of Ethacridine Lactate Monohydrate as a Veterinary Active?

Ethacridine lactate monohydrate differs from halogenated and biguanide antiseptics because its activity is not based on free halogen release or general membrane lysis but on planar acridine intercalation into microbial nucleic acid. Published comparative data indicate that this mechanism gives more selective coverage than chlorhexidine digluconate, with higher activity against Gram-positive cocci and less robust activity against Pseudomonas and spore-forming organisms. The presence of the lactate counterion provides a pH range in aqueous solution of 4.5–6.5 at 0.1% w/v, which is compatible with many veterinary irrigation protocols but insufficiently acidic to prevent hydrolysis of the acridine ring under terminal heat.

The light sensitivity of the acridine chromophore is a critical operational boundary. Aqueous solutions exposed to unfiltered daylight in clear glass develop measurable photodegradation within 12–24 h; amber glass or opaque fill lines are required for bulk solution holding. The compound is also sensitive to strong oxidising agents; hydrogen peroxide and sodium hypochlorite destroy the yellow chromophore and should not be used for sanitising equipment holding ethacridine lactate. In compounding, the API should not be triturated with strong alkalis because the free base precipitates and the lactate salt is neutralised.

Within the acridine family, ethacridine lactate monohydrate is a single defined entity, unlike acriflavine, which is a mixture of 3,6-diamino-10-methylacridinium chloride and proflavine. The 2-ethoxy substituent in ethacridine raises lipid solubility relative to proflavine and reduces the irritancy observed with simple aminoacridines; the lactate salt avoids the chloride counterion, which can promote corrosion in stainless steel. These differences matter in formulation because ethacridine lactate monohydrate can be incorporated into aqueous vehicles without the precipitation that occurs when proflavine salts are mixed with chloride-rich buffers.

Dry Granulation, Roller Compaction and Premix Dilution Behaviour

Manufacture of tablets and capsules is limited by the crystal habit of ethacridine lactate monohydrate. The plate-like crystals flow poorly through gravity-driven feeds, so direct compression requires a force-feeder equipped with rotating stirrer bars and an acceptably low lubricant concentration. Magnesium stearate above 0.5% w/w delays disintegration beyond 15 min in the disintegration apparatus and reduces tensile strength, while colloidal silicon dioxide at 0.2–0.5% w/w improves flow without excessive particle-size interference.

Wet granulation with aqueous binders is generally avoided because partial dissolution and drying produce needle-like recrystallised material that increases punch-filling variability and causes picking. Dry granulation by roller compaction is preferred for ethacridine lactate tablets; ribbon density is maintained between 1.10 and 1.25 g/cm³, and milled granules are screened through a 0.8 mm sieve. Hardness of the final tablet is typically specified between 60 and 80 N for intrauterine administration, but veterinary product developers must confirm disintegration in the target environment because compendial disintegration in water does not predict behaviour in viscous uterine fluid.

For oral powders, granules and premixes, stepwise geometric dilution is mandatory because the API is active at low concentrations and segregation occurs if coarse crystalline material is added directly to feed. A first preblend at 10% w/w API on lactose monohydrate is prepared by tumble blending for 20 min, followed by a second preblend at 1% w/w and final feed with a coefficient of variation not exceeding 5.0%. The final premix should be tested for uniform distribution according to the medicated feed sampling scheme adopted by the relevant Veterinary Good Manufacturing Practice guideline.

Hard gelatin capsule filling is performed with dry-granulated material with a particle size d90 below 180 µm to avoid bridging in the dosator. The monohydrate is hygroscopic above 60% RH; open handling in uncontrolled humidity should be limited to 8 h or less. Capsule content uniformity is evaluated by USP chapter 905, with the acceptance value determined by the labelled dose and batch size; segregation during capsule filling is monitored by sampling at 10 evenly spaced intervals across the run.

On production-scale rotary presses equipped with paddle force-feeders, ethacridine lactate monohydrate tablets containing high lactose loads show a tendency to cap when turret speed exceeds 30 rpm and pre-compression force is below 5 kN. The failure mode is attributed to air entrapment between the plate-like crystals. Raising the pre-compression force to 5–8 kN and reducing turret speed to 20–25 rpm improves tablet hardness and lowers friability below 0.8% after 100 revolutions in the friabilator. Batch-to-batch variance in particle-size distribution from different recrystallisation lots can shift the required compaction force, so roller-compacted granules are preferred when the API fraction exceeds 20% w/w.

When Terminal Sterilisation of Aqueous Veterinary Injectables Is Required

Injectable solutions are prepared by dissolving ethacridine lactate monohydrate in Water for Injections at 45–55°C with moderate agitation at 150–200 rpm. The solution is cooled to 20–25°C before pH adjustment to 5.0–6.5 with dilute sodium hydroxide or hydrochloric acid. Sterilising filtration through a 0.22 µm polyethersulfone membrane is the preferred method because terminal autoclaving accelerates hydrolytic and oxidative degradation; nylon membranes should be avoided because the planar acridine moiety binds to the membrane and reduces yield.

If terminal sterilisation is unavoidable, the solution is packed in amber Type I glass under a nitrogen headspace and autoclaved at 121°C for 15 min. The pH before autoclaving must remain below 6.5; higher pH values produce rapid colour darkening and visible particulate formation. Post-sterilisation absorbance at 450 nm is monitored as a stability indicator. Published data for terminal sterilisation of ethacridine lactate at concentrations above 0.2% w/v is limited, and aseptic filtration remains the default route for higher-strength injectable products.

Membrane flux decline during sterilising filtration has been observed when the solution is cooled too rapidly below 25°C or when the pH is adjusted above 6.5. The acridine base aggregates as fine needle clusters that deposit on the upstream side of the 0.22 µm membrane and restrict flow. A controlled cooling ramp of 0.5–1.0°C/min and filtration at 25–30°C maintains the monomer-dimer equilibrium in solution and allows 50–70 L/m² throughput before change-out of the membrane cartridge. These values are process guidance from pilot-scale batches and should be qualified for each membrane vendor.

For topical and cavity irrigation, the veterinary API is diluted to 0.05–0.1% w/v in sterile water or normal saline. Solutions should be prepared immediately before use where possible, or stored in amber glass for no more than 24 h. The product is not a high-level sterilant for surgical instruments and should not be used as a substitute for autoclaving or glutaraldehyde-based disinfection. It is incompatible with anionic surfactants, strong oxidisers, and concentrated halide solutions. When these solution formulations are filled into plastic containers, low-density polyethylene and polypropylene are acceptable after extraction testing according to the relevant veterinary drug registration requirements.